Among them, interleukin-6 (IL-6) has long been recognized as a key modulator of the pro-inflammatory process, and it has recently been reported to be involved in modulating bone homeostasis in inflammatory diseases; in particular, it has been developed as a therapeutic target for immune disorders, including rheumatoid arthritis [26,27]. The gene discussed is IL6; the disease is immune system disorder.